This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
September 8, 2011 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (
http://www.oramed.com), a developer of oral delivery systems, announced today that
Roy Eldor, M.D., the Director of Medical Affairs at Oramed, is scheduled to present at the Rodman & Renshaw 13
th Annual Global Investment Conference in the
Israel track. The conference will be held at the Waldorf Astoria Hotel in
New York City.
Dr Eldor is scheduled to speak on
Tuesday September 13, 2011 at
1:35 p.m. ET in the Sutton Suite. He will discuss Oramed's strategic initiatives, updates and product pipeline.
For more information about the conference please visit
http://www.rodm.com/2011conferenceAbout Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at
Jerusalem's Hadassah Medical Center. Oramed's corporate and R&D headquarters are based in
For more information, please visit
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the Company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the Company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in such forward looking statements. The Company undertakes no obligation to update or revise any forward-looking statements.